Table 1.

Characteristics at randomisation in the subset of participants in SMART with measured cystatin-C

Characteristics of participants from SMART with measured cystatin-C: Comparison of DC and VS arms; all factors measured at randomisation

		Drug conservation N=249		Virologic suppression N=250
		N	%	N	%
Gender	Female	72	29.9	74	29.6
Race	Black	131	52.6	121	48.4
	White	86	34.5	93	37.2
	Other	32	12.9	26	14.4
Mode of	Same sex	110	44.2	113	45.2
Infection1	Opposite sex	132	53.0	132	52.8
	IDU	29	11.7	25	10.0
	Blood	13	5.2	13	5.2
	Other	15	6.0	17	6.8
Hepatitis	B positive	11	4.4	8	3.2
	C positive	50	20.1	44	17.6
Prior AIDS		71	28.5	68	27.2
HIV RNA ≤400		142	57.0	136	54.4
Cardiovascular	Smoker	103	41.1	111	44.4
Disease risk	Diabetes	22	8.8	24	9.6
Factors	Prior cardiovascular disease	0	0	0	0
	Blood pressure treatment	60	24.1	76	30.4
	Lipid lowering treatment	41	16.5	45	18.0
Antiretroviral	Naïve	16	6.4	15	6.0
History	Protease-inhibitor exposed	170	68.3	158	62.8
	Non-nucleoside exposed	158	63.5	159	63.2
ART at	On antiretrovirals	182	73.1	188	75.2
Randomisation2	Protease inhibitor	77	42.3	89	47.3
	Non-nucleoside	99	54.4	90	47.9
	Protease inhibitor+non-nucleoside	11	6.0	13	6.9

		Drug conservation		Virologic suppression
		Median	IQR	Median	IQR
Age	(years)	44	38-52	44	38-50
CD4	(cells/mm3)	532	432-720	550	430-743
CD4 nadir	(cells/mm3)	250	133-350	267	167-386
HIV RNA viral load	Log10 copies/ml	2.60	1.70-4.00	2.60	1.88-3.75
Total cholesterol	(mg/dl)	181	156-208	183	157-213
HDL cholesterol	(mg/dl)	40	32-47	41	31-50
LDL cholesterol	(mg/dl)	103	85-126	107	86-131
Triglycerides	(mg/dl)	153	93-246	157	106-258
Cystatin-C	(mg/dl)	0.94	0.83-1.09	0.97	0.84-1.11

¹Patients can be classified as belonging to more than one risk group

²% of those on antiretrovirals at randomisation